Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation Study of CCX140-B in Primary FSGS with Nephrotic Syndrome
2017-003022-32Phase 2Terminated
- Sponsor
- ChemoCentryx
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ilacirnon in focal segmental glomerulosclerosis (FSGS) and nephrosis, sponsored by ChemoCentryx. Primary endpoint: Primary efficacy endpoint: effect of CCX140-B on proteinuria. Started Aug 2019; status: terminated.
02
Drugs
ilacirnon
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosis
Beyond the preview
Go deeper on 2017-003022-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003022-32.